Richard Whittington, M.D.
Associate Professor of Radiation Oncology
Chief of Radiation Oncology
Philadelphia VA Medical Center
(affiliated with University of Pennsylvania School of Medicine)
University and Woodland Avenues
Philadelphia , PA 19104
Phone: 215-823-5855
Fax: 215-823-4117
Education
- B.A. Biology and History, Rice University Houston, TX 1972
- M.D. Jefferson Medical College, Philadelphia PA 1976
- Intern Internal Medicine, Hahnemann Medical College Hospital, Philadelphia, PA 1976-1977
- Resident Internal medicine, Hahnemann medical College Hospital, Philadelphia, PA 1977-1979
- Resident Radiation Therapy, Thomas Jefferson University Hospital, Philadelphia, PA 1979-1981
- Chief Resident Radiation Therapy, Thomas Jefferson University Hospital, Philadelphia, PA 1981
Board Certifications
- American Board of Internal Medicine, 1979
- American Board of Radiology, Radiation Oncology, 1982
- American Board of Radiatiology, Radiation Oncology Recertification, 2000
Areas of Interest
I specialize in the treatment of genitourinary and gastrointestinal tumors. I am a clinician-reseracher whose research interests center on the treatment of locally advanced tumors integrating chemotherapy and targeted therapies into radiation regimens with or without surgery.
Publications :
Altschuler, M.D., and Whittington, R.: Interactive Statistical System and Method for Producing Expert Decisions. US Government Patent 5,005,143 Issued 2 April, 1991.
D'Amico AV. Whittington R. Malkowicz SB. Weinstein M. Tomaszewski JE. Schultz D. Rhude M. Rocha S. Wein A. Richie JP. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. Journal of Urology. 166(6):2185-8, 2001.
Cheung R. Altschuler MD. D'Amico AV. Malkowicz SB. Wein AJ. Whittington R. ROC optimization may improve risk stratification of prostate cancer patients. Urology. 57(2):286-90, 2001.
D'Amico AV. Chen MH. Malkowicz SB. Whittington R. Renshaw AA. Tomaszewski JE. Samofalov Y. Wein A. Richie JP. Lower pr ostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a pr ostatic specific antigen level of 4 ng/ml. or less. Journal of Urology. 167(5):2025-30, 2002.
Jones HA. Metz JM. Devine P. Hahn SM. Whittington R. Rates of unconventional medical therapy use in patients with pr ostate cancer: standard history versus directed questions. Urology. 59(2):272-6, 2002.
Cross CK. Shultz D. Malkowicz SB. Huang WC. Whittington R. Tomaszewski JE. Renshaw AA. Richie JP. D'Amico AV. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the pr ostate. Journal of Clinical Oncology. 20(12):2863-8, 2002.
Robnett TJ. Whittington R. Malkowicz SB. Brereton HD. Van Arsdalen K. Drach G. Wein AJ. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 pr ostate cancer. International Journal of Radiation Oncology, Biology, Physics. 53(5):1146-51, 2002.
D'Amico AV. Whittington R. Malkowicz SB. Cote K. Loffredo M. Schultz D. Chen MH. Tomaszewski JE. Renshaw AA. Wein A. Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 95(2):281-6, 2002
Lieberfarb ME. Schultz D. Whittington R. Malkowicz B. Tomaszewski JE. Weinstein M. Wein A. Richie JP. D'Amico AV. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for pr ostate-only radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 53(4):898-903, 2002.
Smith RP, Devine P, Jones H, et al. Internet Usage by Prostate Cancer Patients Undergoing Radiation Therapy. Urology, 62:273-277, 2003.
» TOP
© University of Pennsylvania | School of Medicine | University of Pennsylvania Health System